A Randomized, Open label Clinical Study to Evaluate Efficacy and Safety of PNB-001 in Patients with moderate COVID-19 Infection
Latest Information Update: 10 Dec 2020
Price :
$35 *
At a glance
- Drugs PNB 001 (Primary)
- Indications COVID-19 pneumonia; COVID-19 respiratory infection
- Focus Therapeutic Use
- Sponsors PNB Vesper Life Science
- 02 Dec 2020 Status changed from not yet recruiting to recruiting.
- 27 Nov 2020 New trial record